Barbara S Schwartzberg1, Daniel T Chin2, Paige L Dorn3, David S Herron3, Kathryn T Howell2, Tyler J Kemmis4, Stephanie A Miller5, Joyce A Moore6, Devchand Paul7. 1. Department of Surgery, Sarah Cannon Research Institute at Rose Medical Center, Denver, CO, USA. Electronic address: scmibs@gmail.com. 2. Department of Radiation Oncology, Rocky Mountain Cancer Centers, Denver, CO, USA. 3. Department of Radiation Oncology, Sarah Cannon Research Institute at Rose Medical Center, Denver, CO, USA. 4. Department of Radiation Oncology, Sisters of Charity of Leavenworth Health System, Inc., Denver, CO, USA. 5. Department of Surgery, Sarah Cannon Research Institute at Rose Medical Center, Denver, CO, USA. 6. Department of Surgery, Sarah Cannon Research Institute at Sky Ridge Medical Center, Lone Tree, CO, USA. 7. Department of Medical Oncology, Rocky Mountain Cancer Centers, Denver, CO, USA.
Abstract
BACKGROUND: American Society for Radiation Oncology (ASTRO) suitability criteria for accelerated partial breast irradiation (APBI) and the 21-gene recurrence score (RS) were evaluated for prognostic and predictive benefit in IORT patients. METHODS: Outcomes of 184 patients completing IRB approved IORT protocol were retrospectively reviewed. Data included demographics, histopathology, RS, adjuvant therapy, locoregional (LRR) and distant recurrences (DR), and breast cancer-specific survival. RESULTS: There were 10 (5.4%) breast cancer recurrences, including one breast cancer-specific death. All 184 patients were classified by ASTRO suitability criteria (suitable: 64% (5 LRR), cautionary: 30% (3 LRR), unsuitable: 6.0% (1 LRR, 1 DR leading to death). RS were available in 114 estrogen receptor positive patients (<11: 22% (1 LRR), 11-25: 63% (1 LRR), 26-30: 9%, >30: 6%). Mean follow-up was 55 months. CONCLUSIONS: ASTRO suitability criteria for APBI and RS were useful in making prognostic and therapeutic recommendations for patients considering IORT.
BACKGROUND: American Society for Radiation Oncology (ASTRO) suitability criteria for accelerated partial breast irradiation (APBI) and the 21-gene recurrence score (RS) were evaluated for prognostic and predictive benefit in IORT patients. METHODS: Outcomes of 184 patients completing IRB approved IORT protocol were retrospectively reviewed. Data included demographics, histopathology, RS, adjuvant therapy, locoregional (LRR) and distant recurrences (DR), and breast cancer-specific survival. RESULTS: There were 10 (5.4%) breast cancer recurrences, including one breast cancer-specific death. All 184 patients were classified by ASTRO suitability criteria (suitable: 64% (5 LRR), cautionary: 30% (3 LRR), unsuitable: 6.0% (1 LRR, 1 DR leading to death). RS were available in 114 estrogen receptor positive patients (<11: 22% (1 LRR), 11-25: 63% (1 LRR), 26-30: 9%, >30: 6%). Mean follow-up was 55 months. CONCLUSIONS: ASTRO suitability criteria for APBI and RS were useful in making prognostic and therapeutic recommendations for patients considering IORT.
Authors: Andrea Brown; Elizabeth J Buss; Christine Chin; Gaotong Liu; Shing Lee; Roshni Rao; Brett Taback; Lisa Wiechmann; David Horowitz; Julie C Choi; Leah M Katz; Eileen P Connolly Journal: Front Oncol Date: 2022-06-29 Impact factor: 5.738
Authors: Matthew G Davey; Eoin F Cleere; John P O'Donnell; Sara Gaisor; Aoife J Lowery; Michael J Kerin Journal: Breast Cancer Res Treat Date: 2022-04-15 Impact factor: 4.624